Switzerland’s Commitment to Healthcare as a Leader in Health Spending and Patent Application

Switzerland's commitment to quality in the pharmaceutical industry

Why US Biotechs have been choosing Switzerland for over 60 years: An Interview with Jacqueline Hess

Three key takeaways from the National Council Health Commission

Article 71 KVV: The case-by-case approach to reimburse pharmaceuticals – a Swiss specialty

Meet Swizzard’s CEO Michael Zürcher at BIO-Europe Spring in Basel

Market Access in Switzerland – or how to include medical breakthroughs on the specialties list

Bettina Schelbert joins Swizzard as Commercial Director

Swizzard in 2022

The Swizzard Pharma AG team wishes a Merry Christmas!

"Enabling collaboration among member companies is the strength and success of the shqa."

Three reasons why pharmaceutical companies should consider the Swiss healthcare market

Swizzard co-founds SMS2DACH network together with MArS (Germany) and Supersonic (Austria)

"Health markets are becoming the drivers of a new economic era."

Julia Mühlethaler joins Swizzard as Design Leader

Swizzard Insight No. 5: How to bring medical breakthroughs to Switzerland faster

Swizzard welcomes Arne Holicki as Business Technology Leader

Karin Senn joins Swizzard as Medical Director

Swizzard’s celebrating an exciting milestone – we just signed our 10th client!

Meet David Hoffmann, member of the Board of Directors & Corporate Secretary of Swizzard Pharma AG